Expert insight by Dr Karim Fizazi on incorporating AR-targeted therapy into the management of nonmetastatic CRPC from Clinical Care Options (CCO)
ARV-110 shows promising activity in patients with resistance to second-generation AR treatments, from ASCO 2020 as reported by Clinical Care Options (CCO)
Results from ARAMIS trial with darolutamide plus ADT vs placebo plus ADT in patients with nonmetastatic CRPC, from ASCO 2020 as reported by Clinical Care Options (CCO)
Get a preview of key studies at ASCO 2020 from experts in both solid tumors and hematologic malignancies from Clinical Care Options
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.